The EU opened a formal antitrust investigation into Amazon on Wednesday centered on how the e-commerce giant uses merchants' data.Technologyread more
Investors are keen to find out how looming interest rate cuts will impact the second biggest U.S. lender by assets.Financeread more
Turo is a peer-to-peer car-sharing firm that is often referred to as the Airbnb for cars.Technologyread more
Mortgage interest rates surged last week to their highest level in a month, and consequently homebuyers turned on their heels.Real Estateread more
Ascending triangle patterns have been appearing across the stock market, and they tend to be precursors to higher prices, says Miller Tabak's Matt Maley.Trading Nationread more
U.S. officials see the deal as a threat to NATO, for which Turkey provides the second-largest military.World Politicsread more
Google's services have been blocked in China for several years, but the company still has a business there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
"The charts, as interpreted by Carley Garner, suggest that the upside in the stock market has gotten more limited," Jim Cramer says.Mad Money with Jim Cramerread more
China may have signaled it's going more hard-line on trade, but it could be a good thing, former U.S. negotiator Clete Willems told CNBC.World Economyread more
Support for U.S. President Donald Trump increased slightly among Republicans after he lashed out on Twitter over the weekend in a racially charged attack on four minority...Politicsread more
A key read on the industry, the Architecture Billings Index, fell into negative territory in June, according to the American Institute for Architects. Inquiries for new...Real Estateread more
Shares of biotech company Illumina spiked 8 percent Wednesday after the company handily beat Wall Street estimates a day earlier.
The stock was the second-biggest gainer in the S&P 500, and added the most gains to the S&P health care sector. Shares of the genetic sequencing company traded near $162.03, still lower than their 52-week high of $220.86.
The San Diego-based company earned 86 cents per share in the second quarter, up from 80 cents in the same period last year. Revenue came in at $600 million, up 11 percent year over year, the company said.
Analysts polled by Thomson Reuters had expected earnings of 73 cents per share and sales of $593.21 million.
Guidance was soft for the third quarter though, and Illumina said it expects revenue between $625 million and $630 million, below Thomson Reuters consensus expectations of $632 million.
"We delivered solid second quarter financial results with notable strength across our sequencing consumable and array portfolios," Francis deSouza, president and CEO of Illumina said in a statement. "We will continue to focus on our execution to deliver the sequential growth we are forecasting in the second half of the year."
Research and development expenses jumped to $124.6 million from $96.2 million the year before.
Shares of Illumina are down more than 15 percent year to date, and 25 percent year over year.